An Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotrexate in RA Patients Not Responding to Adalimumab Plus Methotrexate (RA-COMPARE)
A Randomized, Controlled Study of Sarilumab and Methotrexate (MTX) Versus Etanercept and MTX in Patients With Rheumatoid Arthritis (RA) and an Inadequate Response to 4 Months of Treatment With Adalimumab and MTX
Sponsor: Regeneron Pharmaceuticals
Terminated
Due to small number of participants entering randomization. Not a safety issue.
Other terminated trials from Regeneron Pharmaceuticals
A PHASE3 clinical study on Rheumatoid Arthritis, this trial is terminated or withdrawn. The trial is conducted by Regeneron Pharmaceuticals and has accumulated 10 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE3
▶ Show 5 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE3
-
Sep 2017 — Jun 2018 [monthly]
Terminated PHASE3
-
Aug 2017 — Sep 2017 [monthly]
Terminated PHASE3
-
Feb 2017 — Aug 2017 [monthly]
Terminated PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE3
First recorded
Apr 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Regeneron Pharmaceuticals
- Sanofi
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
A Coruña, Spain , Amiens, France , Ashkelon, Israel , Athens, Greece , Auckland, New Zealand , Bacau, Romania , Bangkok, Thailand , Bangkok Noi, Thailand , Barnsley, United Kingdom , Battle Creek, United States and 185 more locations